跳至主要内容
临床试验/NCT02280135
NCT02280135已完成1 期

Phase I Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa

Red de Terapia Celular2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2014年11月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
8
试验地点
2
主要终点
Rate of serious and non-serious adverse events related with the use of bone marrow mononuclear cells in patients with retinitis pigmentosa

研究概览

简要总结

The purpose of this study is to evaluate the safety of intravitreal injection of autologous bone marrow stem cells in patients with retinitis pigmentosa by a prospective, single-center, randomized, parallel, double-blind, phase I placebo-controlled clinical trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Retinitis Pigmentosa bilateral diagnosis.
  • Visual acuity (measured with ETDRS) less than or equal to 20/70 and visual field below 30° central in both eyes.
  • Signed informed consent
  • Warranty sufficient adherence to protocol. It must fulfill all inclusion criteria.

排除标准

  • Concurrence of any systemic or ocular disease that precludes or affects tracking study variables. Specifically retinal involvement with diabetes mellitus, glaucoma, macular degeneration or age.
  • Eye surgery in the previous 6 months.
  • Patients who are pregnant.
  • Patients with active lactation.
  • Physically fertile patients, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle or sexual orientation excludes sexual intercourse with a man and women whose partners have been sterilized by vasectomy or other methods, UNLESS tHEY are using a reliable contraceptive method. This birth control method can be:
  • Complete abstinence from sexual intercourse
  • Surgical sterilization (tubal ligation)
  • Surgical sterilization partner (vasectomy)
  • Implanted or injectable hormonal contraceptives and oral.
  • Patients with cardiac disease, renal, hepatic, systemic, immune that might influence the survival of patients during the test.
  • Positive serology for hepatitis B, hepatitis C or HIV.
  • Clinical criteria or anesthetics that contraindicate the sedation or the extraction of BM (Altered coagulation system or anticoagulated patient with inability to withdraw anticoagulation, hemodynamic instability, altered skin in the puncture site, etc.)
  • Participation in other clinical trials.
  • Inability to sign informed consent or understanding.

结局指标

主要结局

Rate of serious and non-serious adverse events related with the use of bone marrow mononuclear cells in patients with retinitis pigmentosa

时间窗: 12 months from baseline

次要结局

  • Visual acuity (VA): Test ETDRS (Early Treatment Diabetic Retinopathy Study).(12 months from baseline)
  • Study eye fundus: Made by Retinography and Angiography fluorescein.(12 months from baseline)
  • Visual evoked potentials with Pattern Reversal (VEP) (altered / no altered).(12 months from baseline)
  • Quality of Life: Questionnaire VFQ-25 (Visual Function Questionnaire-25).(12 months from baseline)
  • Color Vision: Ishihara Color Test.(12 months from baseline)
  • Electrical retinal function: electroretinogram (ERG) (altered / unaltered).(12 months from baseline)
  • Contrast sensitivity: CSV-1000E.(12 months from baseline)
  • Width of retinal macula layer and nerve fiber: Measured with Optical Coherence Tomography Spectral domain (OCT)(Topcon 3D OCT-2000 Spectral Domain OCT).(12 months from baseline)
  • Visual field (VF) and macular sensitivity (The Humphrey perimeter).(12 months from baseline)
  • Intraocular pressure (IOP): measured in mm Hg with applanation tonometer Haag Streit AT 900.(12 months from baseline)
  • Examination of the anterior and posterior pole: Made with biomicroscopy (BMC).(12 months from baseline)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验